OmniAb (NASDAQ:OABIW – Get Free Report) is expected to issue its results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $4.6930 million for the quarter.
OmniAb Price Performance
NASDAQ OABIW traded down $0.01 on Tuesday, reaching $0.08. OmniAb has a one year low of $0.04 and a one year high of $0.29. The business has a 50 day moving average of $0.09 and a two-hundred day moving average of $0.09.
About OmniAb
OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.
At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.
Further Reading
- Five stocks we like better than OmniAb
- GLP-1 Demand Is Creating a New Dividend Angle in These 4 Logistics Stocks
- Tether Strikes Gold: Crypto’s Physical Pivot
- Jersey Mike’s Serves Fresh Gains After IPO Stumble
- 3 Drone Stocks That Should Soar After the Summer Slump
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
